IP Offerings Logo

Patent MarketPlace: Pharmaceutical Patents for Sale

Mini-Tablet Dispenser (Balda Medical): International Patent Portfolio

The new mini-tablets in which many drugs are being prescribed – drugs for leukemia, epilepsy, and heart disease are just three – combine the advantages of solid and liquid formulations. They are easy to swallow and provide an accurate dosage, but do not carry the risk of over- or under-dosage that liquids present.

What is needed is a dispenser specifically for this new generation of mini-tablets, and that what this international patent portfolio creates. The dispenser covered by this portfolio stores and dispenses one mini-tablet at a time without breaking or crushing tables in the process. It has an activation lock to prevent misuse. Its rotational design insures controlled dosage of the mini-tablets it holds and it provides visual control of the dosage. The unit is easily locked to secure the tablets, and it is compact enough to be easily stored in a pocketbook.

Patent Portfolio

Any manufacturer of pharmaceutical packaging could use this portfolio to introduce the first packaging product specifically designed to meet the needs of those with a prescription drug in mini-tablet form.

Opioid Medications to Prevent Overdose or Death During Treatment (Presti): International Patent Portfolio

The U.S. Department of Health and Human Services reports that deaths from drug overdose have risen steadily over the past two decades to the point that they have become the leading cause of deaths from injury in the United States. Deaths from opioid overdoses have surpassed automobile accident fatalities, the leading cause of injury deaths in U.S. for the last century. Worse yet, many opioid addicts enter treatment, but then overdose during treatment when they self-medicate with alcohol. According to the Centers for Disease Control (CDC), nearly one quarter of fatal prescription opioid overdoses in the U.S. are associated with patients making the all-too-common mistake of drinking alcohol while medicated. When combined, alcohol and opioids interact in the brain increasing the risk of respiratory depression and death.

This portfolio aims to prevent opioid deaths head-on by solving this critical, but previously unaddressed, dimension of the opioid crisis. It includes several combination drug therapies that reduce the likelihood of an alcohol-mediated opioid overdose or death during maintenance therapy for management of pain or opioid use disorder. It covers a single composition comprising an effective amount of one or more opioid medications and an effective amount of one of 20 aldehyde dehydrogenase inhibitors or one of 65 opioid medications. It also includes a combination medication comprised of an effective amount of one or more opioid medications, an effective amount of one or more aldehyde dehydrogenase inhibitors, and a pharmaceutical carrier.

This extensive portfolio additionally includes a combination medication that is comprised of one or more opioid medications from 1 to 200 mg, a disulfiram or pharmaceutically acceptable salt from 50 to 250 mg, and a carrier. Specifically directed at reducing an alcohol-mediated opioid overdose or death during maintenance therapy for pain management, the portfolio covers a single composition comprised of one or more opioid pain medications from 1 to 200 mg and a disulfiram or pharmaceutically acceptable salt from 50 to 250 mg that prevents alcohol consumption in the patient. There are additional formulations in three pending patent applications.

Patent Portfolio

This portfolio offers a pharmaceutical company the opportunity to introduce the next generation of opioid treatments – a regimen that specifically addresses opioid patients that face severe pains issues during treatment at high risk of drinking alcohol during their treatment for pain or addiction.

Nutraceutical Treatment for Gout (Truscott): U.S. and European Patents

Gout is a form of inflammatory arthritis that is caused by excess uric acid in the blood that crystallizes in joints and other tissues. Among those with gout, 90% have kidneys that don’t adequately remove uric acid from their urine, while 10% have high uric acid levels because their bodies produce too much uric acid. Between eight and nine million Americans suffer from gout – and millions more in Europe. Gout can be very painful – even disabling. Most treatments for gout address the pain and inflammation caused by the condition, not the root cause of the disease!

This portfolio covers a safe and effective treatment for gout that is composed of natural ingredients – celery seed extract, cherry extract, and elemental lithium in a lithium salt. The components work synergistically to inhibit painful uric acid crystals by three different modes of action: Inhibition of uric acid formation (celery seed extract), increase in uric acid elimination from the body (cherry extract), and interference with crystallization itself (lithium). Since the ingredients are all-natural, a gout treatment based on these patents can be sold over-the-counter without a prescription.

U.S. Patent No. 9,149,500 and European Patent 2303302 for a “Method and process for relieving or preventing symptoms” would enable any pharmaceutical supplier or natural remedy manufacturer to bring a treatment for gout to the market very quickly!

Urinary Tract Infection Prevention and Treatment (Biomedicals Science Sweden): International Patent Portfolio

In the science fiction thriller The Andromeda Strain, scientists attempting to stop an infection from outer space discover that the disease can only survive in a narrow pH range. The same is true of many infections here on earth including bacteria that can make its way up the urinary tract to infect the bladder (causing cystitis) or kidneys (causing pyelonephritis). Controlling the pH level in the patient’s urinary tract can prevent bacteria from becoming an infection.

This portfolio covers alternating administrations of a pH-increasing agent with the administration of a pH-decreasing agent to the patient via a mannose solution. The pH-increasing agent is administered at a dosage of about 0.1 to 20 grams per day, while the pH-decreasing agent is administered to at a dosage of about 0.1 to 20 grams per day, and the mannose or other solution is administered to at a dosage of about 0.1 to 50 grams per day.

Urinary Tract Infection Portfolio

This portfolio can be developed into a product that is sold over-the-counter in pharmacies or is used in physician’s offices as a pre-treatment prior to prescribing antibiotics. It can also be used in hospitals after surgery to lower the risk of infection and as a product for catheter patients, significantly lowering the use of antibiotics among this high-risk infection group. This portfolio will enable any drug manufacturer to introduce a product that totally prevents, or very quickly and effectively treats, a urinary tract infection without the use of antibiotics and their resulting side effects.

Treatment for Afflictions of the Central Nervous System (Numazawa): U.S. and Japanese Patents

It is not uncommon for a drug that was originally developed to treat one disease or condition to be found to also treat another disease or condition. For example, minoxidil, the active ingredient in Rogaine® (the popular treatment for male pattern baldness) was originally developed to treat high blood pressure! This is known as “drug repositioning.”

This patent portfolio addresses new uses for two existing drugs – Methocarbamol and Chlorphenesin Carbamate – for the treatment of central nervous system afflictions such as mood disorders, mental disorders, chronic fatigue syndrome, depression, and Alzheimer’s. The inventor has three published medical research papers documenting the effectiveness of this patented drug combination.

This portfolio includes U.S. Patent No. 11,364,218 for a “Method of treating or preventing mood disorders, mental disorders, and/or chronic fatigue syndrome” and Japanese Patent 6216913 for a “Pharmaceutical composition.” Since the two drugs on which the patents are based are already FDA-approved, the acquirer of the patents should be able to go to market with a drug for the treatment of depression and Alzheimer’s fairly quickly.

Rogaine is a registered trademark of Johnson & Johnson Services, Inc.

Production of Very Pure HMR and NTG Lignans (Montisera): International Patent Portfolio

Lignans are a little-known group of low molecular weight polyphenols that are derived from trees and other ligneous plants. HMR (hydroxymatairesinol) lignans are a powerful antioxidant and immune system booster that is used in by humans as well as dogs and cats. It is also an enterolactone precursor with anticancer activities. Testing has shown that HMR lignans decrease the volume of induced tumors and stabilize established tumors – and prevent the development of new tumors – in rats. HMR lignans and NTG (nortrachelogenin) lignans are also key ingredients in natural cosmetics that offer anti-aging properties. Research has shown promise for NTG lignans in treating prostate cancer.

The challenge is refining lignans through the fractionation of knotwood extract. This portfolio covers a process that in which hydrophilic extract is extracted with a lipophilic solvent that removes lipophilic impurities. The portfolio also covers the use of liquid-to-liquid extraction for the purification of hydrophilic knotwood extract. The patented process provides a purified extract that contains more than 90 % lignans, flavonoids, and stilbenes, and less than 10 % in impurities.

Patent Portfolio